Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Siplizumab · MEDI-507

Monoclonal antibody · Immune activation, directed at CD2 · developed by MedImmune LLC

Early Phase 1 Most advanced trial

1 Registered trials

What is Siplizumab?

Siplizumab is a humanized IgG1 monoclonal antibody that binds CD2, a receptor on T cells and NK cells. Binding triggers an immune response that lyses CD2-positive cells and suppresses activated T cell growth. It has been studied in kidney transplant recipients, including for immunosuppression and transplant tolerance.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: MEDI-507
Drug type: Monoclonal antibody
Targets: CD2
Mechanism: Immune activation, directed at CD2
Pathways: T cell activation, immune suppression
Therapy area: Renal & urology
Developer: MedImmune LLC
In trials of: ELDN
FDA status: Investigational, not approved in the US. Most advanced trial: Early Phase 1
UNII: KUW1QG1ZM3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06972069	Early Phase 1	Kidney Failure	Active not recruiting	ELDN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

ImmunosuppresionImmunosuppression After Kidney TransplantationKidney FailureTransplant Recipient (Kidney)Transplant Tolerance

Other drugs acting on CD2

Anti-Thymocyte Globulin FDA approved

Sources

NCI Thesaurus

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z